SCHEMBL6696486

SCHEMBL6696486

Cc1ccc(NC(=O)Nc2cc(C(=O)N3CCNCC3)ccc2N2CCN(C(c3ccccc3)c3ccccc3)CC2)c(C)c1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.47
HTT P42858 1/20 0.47
LMNA P02545 3/20 0.46
TP53 P04637 1/20 0.46
ALDH1A1 P00352 4/20 0.46
KMT2A Q03164 3/20 0.44
HPGD P15428 1/20 0.44
OPRD1 P41143 6/20 0.43
CACNA2D1 P54289 1/20 0.43
CACNA1B Q00975 1/20 0.43
CACNB1 Q02641 1/20 0.43
PANK3 Q9H999 1/20 0.42
MAOB P27338 1/20 0.42
MAPT P10636 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6701311 0.89 KMT2A (0.45) LMNATP53ALDH1A1KMT2AHPGD
SCHEMBL5567749 0.88 KMT2A (0.57) POLBTP53ALDH1A1KMT2AHPGD
SCHEMBL6701730 0.88 KMT2A (0.48) LMNATP53ALDH1A1KMT2AHPGD
SCHEMBL6699164 0.86 KMT2A (0.47) ALDH1A1KMT2AHPGDOPRD1MAOB
SCHEMBL6693686 0.86 KMT2A (0.49) ALDH1A1KMT2AHPGDOPRD1MAOB
SCHEMBL6696335 0.85 ALDH1A1 (0.49) LMNATP53ALDH1A1KMT2AHPGD
SCHEMBL6700031 0.85 KMT2A (0.46) HTTLMNAALDH1A1KMT2AHPGD
SCHEMBL6701820 0.85 ALDH1A1 (0.50) POLBLMNATP53ALDH1A1KMT2A
SCHEMBL6698658 0.84 KMT2A (0.50) LMNATP53ALDH1A1KMT2AHPGD
SCHEMBL6702347 0.83 OPRD1 (0.44) LMNATP53ALDH1A1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235855-A1 Phospholipase C inhibitors for use in treating inflammatory disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2004-11-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235855-A1 Phospholipase C inhibitors for use in treating inflammatory disorders PLA2G4C, PLA2G4B, PLA2G5 POLB 2032/4885HTT 4808/4885LMNA 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.